UCSF scientists engineered old fibroblast cells to turn their genes on and off in the same way as young fibroblasts. The old ...

Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.

HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...

HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...

HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...

HOUSTON - FibroBiologics, Inc. (NASDAQ:FBLG) announced Wednesday it has submitted a new patent application to the U.S. Patent and Trademark Office titled "Spheroids For Cartilage Repair," covering a ...

HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...

FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and ...

FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...